Pharmacodynamics of alacepril in healthy cats

J Feline Med Surg. 2017 Jun;19(6):706-709. doi: 10.1177/1098612X16636420. Epub 2016 Feb 29.

Abstract

Objectives The aims of this study were to investigate the pharmacodynamics of alacepril and to determine the appropriate dose for clinical usage in cats. Methods Six experimental cats were used. Each cat received alacepril orally at a single dose of 1 mg/kg, 2 mg/kg and 3 mg/kg. Blood samples were collected before administration and at 2, 4, 6, 8, 12, 24, 36, 48 and 72 h after administration to measure serum angiotensin converting enzyme (ACE) activity. Systolic blood pressure was also measured at the same time point. Results Dose-dependent inhibition of ACE activity was observed. Doses of 2 mg/kg and 3 mg/kg alacepril were considered to effectively inhibit ACE activity. There were no significant differences in systolic blood pressue among groups at any time point. Conclusions and relevance Alacepril 2-3 mg/kg q24h may be an appropriate dosage for clinical use in cats.

MeSH terms

  • Administration, Oral
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / blood
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Blood Pressure / drug effects
  • Captopril / administration & dosage
  • Captopril / analogs & derivatives*
  • Captopril / blood
  • Captopril / pharmacology
  • Cats / blood*
  • Cats / physiology
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Female
  • Male
  • Peptidyl-Dipeptidase A / blood

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Captopril
  • Peptidyl-Dipeptidase A
  • alacepril